BSE - Delayed Quote INR

Wockhardt Limited (WOCKPHARMA.BO)

Compare
1,386.95
-54.20
(-3.76%)
At close: January 10 at 3:41:53 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
29,400,000.00
27,890,000.00
26,460,000.00
32,100,000.00
26,990,000.00
Cost of Revenue
12,060,000.00
11,650,000.00
11,110,000.00
12,670,000.00
11,350,000.00
Gross Profit
17,340,000.00
16,240,000.00
15,350,000.00
19,430,000.00
15,640,000.00
Operating Expense
16,310,000.00
16,540,000.00
16,840,000.00
18,920,000.00
18,710,000.00
Operating Income
1,030,000.00
-300,000.00
-1,490,000.00
510,000.00
-3,070,000.00
Net Non Operating Interest Income Expense
-2,900,000.00
-2,990,000.00
-2,980,000.00
-2,930,000.00
-2,280,000.00
Pretax Income
-2,820,000.00
-4,200,000.00
-6,240,000.00
-4,110,000.00
-5,680,000.00
Tax Provision
130,000.00
520,000.00
-30,000.00
-1,320,000.00
-2,710,000.00
Net Income Common Stockholders
-2,880,000.00
-4,630,000.00
-5,590,000.00
-2,440,000.00
6,860,000.00
Diluted NI Available to Com Stockholders
-2,880,000.00
-4,630,000.00
-5,590,000.00
-2,440,000.00
6,860,000.00
Basic EPS
-19.82
-32.05
-38.79
-20.24
57.11
Diluted EPS
-19.82
-32.05
-38.79
-20.24
56.88
Basic Average Shares
146,618.57
144,252.06
144,064.32
120,560.32
120,143.72
Diluted Average Shares
146,618.57
144,252.06
144,064.32
120,965.01
120,622.98
Rent Expense Supplemental
270,500.00
360,000.00
340,000.00
310,000.00
300,000.00
Total Expenses
28,370,000.00
28,190,000.00
27,950,000.00
31,590,000.00
30,060,000.00
Net Income from Continuing & Discontinued Operation
-2,880,000.00
-4,630,000.00
-5,590,000.00
-2,440,000.00
6,860,000.00
Normalized Income
-1,963,000.00
-3,615,000.00
-2,942,768.00
-1,195,600.00
-1,925,000.00
Interest Income
99,900.00
60,000.00
40,000.00
60,000.00
210,000.00
Interest Expense
2,820,000.00
2,910,000.00
2,920,000.00
2,820,000.00
2,430,000.00
Net Interest Income
-2,900,000.00
-2,990,000.00
-2,980,000.00
-2,930,000.00
-2,280,000.00
EBIT
--
-1,290,000.00
-3,320,000.00
-1,290,000.00
-3,250,000.00
EBITDA
2,220,000.00
940,000.00
-810,000.00
1,180,000.00
-790,000.00
Reconciled Cost of Revenue
12,060,000.00
11,650,000.00
11,110,000.00
12,670,000.00
11,350,000.00
Reconciled Depreciation
2,220,000.00
2,230,000.00
2,510,000.00
2,470,000.00
2,460,000.00
Net Income from Continuing Operation Net Minority Interest
-2,880,000.00
-4,630,000.00
-5,590,000.00
-2,440,000.00
-2,990,000.00
Total Unusual Items Excluding Goodwill
-1,310,000.00
-1,450,000.00
-2,660,000.00
-1,830,000.00
-1,420,000.00
Total Unusual Items
-1,310,000.00
-1,450,000.00
-2,660,000.00
-1,830,000.00
-1,420,000.00
Normalized EBITDA
3,530,000.00
2,390,000.00
1,850,000.00
3,010,000.00
630,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-393,000.00
-435,000.00
-12,768.00
-585,600.00
-355,000.00
3/31/2021 - 4/18/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ORCHPHARMA.BO Orchid Pharma Limited
1,845.95
-2.06%
 
GLAND.BO Gland Pharma Limited
1,784.35
-2.35%
 
UNICHEMLAB.BO Unichem Laboratories Limited
689.85
-1.45%
 
PHARMAID.BO Pharmaids Pharmaceuticals Limited
81.65
-1.99%
 
INDSWFTLTD.BO Ind-Swift Limited
28.09
-4.88%
 
AARTIPHARM.BO Aarti Pharmalabs Limited
669.05
+1.53%
 
AARTIDRUGS.NS Aarti Drugs Limited
429.95
-2.78%
 
GLS.BO Alivus Life Sciences Limited
1,011.10
-1.77%
 
SOLARA.BO Solara Active Pharma Sciences Limited
655.15
-3.89%
 
NECLIFE.BO Nectar Lifesciences Limited
37.60
-0.82%